Navigation Links
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
Date:9/20/2007

pment of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty i
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... importance of dedicated information management systems for radiation ... most recent version of its MOSAIQ® Oncology Information ... Systems Society,s 2012 conference (HIMSS12), Feb. 20-24, in ... comprehensive OIS that centralizes traditional radiation oncology, particle ...
... Feb. 16, 2012  Cardium Therapeutics (NYSE Amex: ... previously announced sale of 17,857,143 shares of its common ... of approximately $5.0 million, before deducting placement agent,s fees ... investors participating in the offering purchased the shares at ...
Cached Medicine Technology:Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting 2Cardium Announces Closing of $5.0 Million Equity Financing 2Cardium Announces Closing of $5.0 Million Equity Financing 3
(Date:12/22/2014)... Physicians in China are most eagerly awaiting a ... lymphoma (NHL), according to a new report from ... MabThera is the only biologic available to treat diffuse ... NHL. , According to Kantar Health’s report, “Biosimilars in ... in China has been growing and is expected to ...
(Date:12/22/2014)... Super Saturday, the last Saturday before ... the busiest day in the 2014 holiday shopping season. ... had a steady pre-Christmas stream of customers, ready to ... , “I definitely intend to take advantage…of the recreational ... who was enjoying The Grass Station’s holiday sale on ...
(Date:12/22/2014)... 22, 2014 Only weeks following the ... mid-western cities to have a battery manufacturer create 29 ... ( http://www.talklocal.com ) is launching in Henderson to ... , “A strong manufacturing sector is going to build ... Singh explained, “and TalkLocal works with small businesses that ...
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Pasadena ... offering consultations for sleep apnea. Drowsy drivers are 15 ... drivers who are well-rested, and some experts believe that ... roads as intoxicated drivers. Unfortunately, millions of Americans may ... American Academy of Sleep Medicine, about 18 million Americans ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... adolescents and young adults finds that an extensive set ... of asthma attacks in participants who both receive care ... This finding differs from previous reports suggesting that ... future asthma attacks. These earlier conclusions, however, were based ...
... of blocking the formation of specific protein clumps that ... been discovered by researchers at the University of Pennsylvania ... they have identified drug-like inhibitors of AD tau protein ... Co-authors Alex Crowe, Research Specialist; Kurt R. ...
... , , Campaign couples power ... , HARRISBURG, Pa., Aug. 10 /PRNewswire-USNewswire/ -- ... Health Action Now campaign with a multimillion-dollar national advertising and grassroots ... dependable, affordable health insurance. The Association,s paid advertising -- available ...
... , PITTSBURGH, Aug. 10 DynaVox Mayer-Johnson, ... for individuals with speech, language and learning disabilities, today ... standard for hand-held speech solutions by bringing together comprehensive ... of mainstream communication features. , , ...
... other contact sports, study finds , MONDAY, Aug. 10 (HealthDay ... about the same rate as in baseball and football, deaths ... common in lacrosse, new research shows. , Lacrosse has swept ... making it the fastest-growing youth sport in the country. The ...
... , , HUDSON, Mass., Aug. 10 ... provider of high performance interconnect solutions for the most ... series circular connectors were selected by SynCardia Systems, Inc. ... to provide critical interconnect reliability for their Freedom(TM) driver, ...
Cached Medicine News:Health News:NIAID media availability: Still searching for predictors of asthma attacks 2Health News:New class of compounds discovered for potential Alzheimer's disease drug 2Health News:New class of compounds discovered for potential Alzheimer's disease drug 3Health News:Multimillion-Dollar AARP Campaign Busts the Myths of the Health Care Debate 2Health News:Multimillion-Dollar AARP Campaign Busts the Myths of the Health Care Debate 3Health News:DynaVox Mayer-Johnson Announces the Xpress 2Health News:DynaVox Mayer-Johnson Announces the Xpress 3Health News:Blows to the Chest Up Death Risk for Lacrosse Players 2Health News:Blows to the Chest Up Death Risk for Lacrosse Players 3Health News:Hypertronics HyperGrip(R) and D Series Connectors Selected for SynCardia's Total Artificial Heart 2
Research Series 2100 Adjustable-volume Pipette,100-1,000 l, single-channel with adjustable-volume setting...
... first Sysmex hematology analyzer designed for a ... its small footprint, closed tube sampling, and ... of whole blood sample, you have a ... the emergency room, surgical suite, or small ...
... The Integrity family of pacemakers ... and truly automatic devices in today's ... combination of automated features and diagnostic ... popular and proven Affinity pacemakers platform. ...
... PT System is an in vitro diagnostic ... results, expressed in seconds and INR units. ... It is intended for use by health ... to monitor patients who are on warfarin-type ...
Medicine Products: